Companies whose shares are expected to trade actively in today’s session are Health Management Associates Inc (NYSE:HMA), SeaChange International (NASDAQ:SEAC), Synergy Pharmaceuticals Inc (NASDAQ:SGYP), PriceSmart, Inc. (NASDAQ:PSMT), Realogy Holdings Corp (NYSE:RLGY) and Durata Therapeutics Inc (NASDAQ:DRTX).
Health Management Associates Inc (NYSE:HMA): The hospital operator issued first quarter revenue estimates that fell short of Wall Street estimates. The company also lowered its outlook for the full year as inpatient admissions fell. It expects $1.48 billion revenues with 12-13 cents in earnings for the first quarter. Analysts were expecting 23 cents per share in earnings with $1.55 billion in sales. Shares tanked 14.22 percent to $10.80 in the early trading session.
SeaChange International (NASDAQ:SEAC): The video software company swung to a fourth quarter profit due to lower operating expenses and strong revenues. However, SeaChange issued pessimistic guidance for the current quarter. Shares skidded 10.60 percent to $10.20 in early trading.
Synergy Pharmaceuticals Inc (NASDAQ:SGYP): The bio-pharmaceutical company plans to offer shares worth $90 million. The company plans to use the proceeds to fund research and development activities. Synergy Pharmaceuticals needs funds to conduct clinical trials for its constipation drug plecanatide. Shares were down 12.29 percent $6.35 in the early session.
PriceSmart, Inc. (NASDAQ:PSMT): The discount-club store chain’s second quarter profits surged 23 percent amid double-digit sales growth. Earnings and sales topped Wall Street expectations. Shares jumped 3.6 percent to $83.08 in the early trading.
Realogy Holdings Corp (NYSE:RLGY): The company’s first quarter earning projections fell short of analysts expectations. Realogy also said that certain funds affiliated to Apollo Global Management will be offering 35 million shares. The company will not receive any proceeds. Shares slipped 6.16 percent to $42.04.
Durata Therapeutics Inc (NASDAQ:DRTX): The pharmaceutical company will be offering $50 million of shares. Proceeds will be used to seek approval in Europe and the U.S. for its drug dalbavancin that can be used to treat skin infections. Shares were down 2.7 percent to $8.15.
